Indication

Philadelphia chromosome positive chronic myelocytic leukemia

Philadelphia chromosome positive chronic myelocytic leukemia (also termed chronic myeloid or myelogenous leukemia) is a clonal myeloproliferative neoplasm affecting the hematopoietic system, predominantly diagnosed in older adults. Read more about Philadelphia chromosome positive chronic myelocytic leukemia

0 drugs 0 manufacturers

Advertisement

Drugs that treat it

Common Philadelphia chromosome positive chronic myelocytic leukemia therapies.

0 drugs

No drugs are available

This indication does not currently contain public drugs.

Filter & compare in the drug finder →Opens the drug finder with Philadelphia chromosome positive chronic myelocytic leukemia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Philadelphia chromosome positive chronic myelocytic leukemia.

Philadelphia chromosome positive chronic myelocytic leukemia (also termed chronic myeloid or myelogenous leukemia) is a clonal myeloproliferative neoplasm affecting the hematopoietic system, predominantly diagnosed in older adults.

It is defined by the presence of the Philadelphia chromosome, an acquired cytogenetic abnormality resulting from a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11.2).

This genetic alteration produces the constitutively active BCR::ABL1 tyrosine kinase fusion oncoprotein, which drives the uncontrolled proliferation and accumulation of mature and maturing granulocytic cells in the bone marrow and peripheral blood.

Patients classically present with marked leukocytosis, anemia, and splenomegaly, with the potential to progress from an indolent chronic phase to an aggressive blastic phase.

Personalize your experience

Follow Philadelphia chromosome positive chronic myelocytic leukemia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it